Recent progress in protein-protein interaction study for EGFR-targeted therapeutics

References

• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134.
   PubMed Web of Science ®Google Scholar
• Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.
   PubMed Web of Science ®Google Scholar
• Roskoski R. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors. Pharmacol Res. 2014;87:42–59.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Coussens L, Hayflick J, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–425.
   PubMed Web of Science ®Google Scholar
• Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002;110(6):775–787.
   PubMed Web of Science ®Google Scholar
• Arkhipov A, Shan Y, Das R, et al.. Architecture and Membrane Interactions of the EGF Receptor. Cell. 2013;152(3):557–569.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354.
   PubMed Web of Science ®Google Scholar
• Bessman NJ, Bagchi A, Ferguson KM, et al. Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor. Cell Rep. 2014;9(4):1306–1317.
   PubMed Web of Science ®Google Scholar
• Burgess AW, Cho H, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12(3):541–552.
   PubMed Web of Science ®Google Scholar
• Ferguson KM, Berger MB, Mendrola JM, et al. EGF activates its receptor by removing interactions that Autoinhibit Ectodomain Dimerization. Mol Cell. 2003;11:507–517.
   PubMed Web of Science ®Google Scholar
• Chung I, Akita R, Vandlen R, et al. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature. 2010;464(7289):783–787.
   PubMed Web of Science ®Google Scholar
• Arkhipov A, Shan Y, Das R, et al. Architecture and membrane interactions of the EGF receptor. Cell. 2013;152(3):557–569.
   PubMed Web of Science ®Google Scholar
• Liu P, Cleveland TE, Bouyain S, et al. A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci. 2012;109(27):10861–10866.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110(6):669–672.
   PubMed Web of Science ®Google Scholar
• Jura N, Zhang X, Endres NF, et al. Catalytic control in the EGF receptor and its connection to general Kinase regulatory mechanisms. Mol Cell. 2011;42(1):9–22.
   PubMed Web of Science ®Google Scholar
• Jura N, Shan Y, Cao X, et al. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A. 2009;106(51):21608–21613.
   PubMed Web of Science ®Google Scholar
• Wilson KJ, Gilmore JL, Foley J, et al. Functional selectivity of EGF family peptide growth factors: Implications for cancer. Pharmacol Ther. 2009;122(1):1–8.
   PubMed Web of Science ®Google Scholar
• Endres NF, Das R, Smith AW, et al.. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell. 2013;152(3):543–556.
   PubMed Web of Science ®Google Scholar
• Jura N, Endres NF, Engel K, et al. Mechanism for activation of the EGF receptor catalytic domain by the Juxtamembrane segment. Cell. 2009;137(7):1293–1307.
   PubMed Web of Science ®Google Scholar
• Doerner A, Scheck R, Schepartz A. Growth factor identity is encoded by discrete coiled-coil rotamers in the EGFR Juxtamembrane region. Chem Biol. 2015;22(6):776–784.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–562.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195–203.
   PubMed Web of Science ®Google Scholar
• Kadamur G, Ross EM. Mammalian phospholipase C. Annu Rev Physiol. 2013;75:127–154.
   PubMed Web of Science ®Google Scholar
• Haj A, Van Zoelen EJJ, Van Leeuwen JEM. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem. 2003;278(37):35781–35790.
   PubMed Web of Science ®Google Scholar
• Polo S. Signaling-mediated control of ubiquitin ligases in endocytosis. BMC Biol. 2012;10(25):1–9.
   PubMed Web of Science ®Google Scholar
• Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284:2–13.
   PubMed Web of Science ®Google Scholar
• Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6(1):32–43.
   PubMed Web of Science ®Google Scholar
• Fischer OM, Hart S, Gschwind A, et al. EGFR signal transactivation in cancer cells. Biochem Soc Trans. 2003;31:1203–1208.
   PubMed Web of Science ®Google Scholar
• Friedländer E, Barok M, Szöllosi J, et al. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett. 2008;116(2):126–140.
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9–S15.
   PubMed Web of Science ®Google Scholar
• Hutchinson RA, Adams RA, McArt DG, et al. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. J Transl Med. 2015;13(217):1–11.
   PubMed Web of Science ®Google Scholar
• FDA and EMA drug information. 2016. http://www.cancer.gov/about-cancer/treatment/drugs/cetuximab http://www.cancer.gov/about-cancer/treatment/drugs/panitumumab http://www.cancer.gov/about-cancer/treatment/drugs/necitumumab http://www.ema.europa.eu/ema/
   Google Scholar
• Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti- epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44(3):1002–1007.
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301–311.
   PubMed Web of Science ®Google Scholar
• Rocha-Lima CM, Soares HP, Raez LE, et al. Special report EGFR targeting of solid tumors. Cancer Control. 1998;2:295–304.
   Google Scholar
• Schmiedel J, Blaukat A, Li S, et al. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008;13(4):365–373.
   PubMed Web of Science ®Google Scholar
• Yang X, Jia X, Corvalan JRF, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor w. Cancer Res. 1999;15(59):1236–1243.
   Google Scholar
• Haigler H, Ash JF, Singer SJ, et al. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci U S A. 1978;75(7):3317–3321.
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38(1):17–23.
   PubMed Web of Science ®Google Scholar
• Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure. 2008;16(2):216–227.
   PubMed Web of Science ®Google Scholar
• Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65(2):622–631.
   PubMed Web of Science ®Google Scholar
• Shah DK. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn. 2015;42(5):553–571.
   PubMed Web of Science ®Google Scholar
• Pack P, Müller K, Zahn R, et al. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J Mol Biol. 1995;246(1):28–34.
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126–1136.
   PubMed Web of Science ®Google Scholar
• Nelson AL. Antibody fragments: hope and hype. MAbs. 2010;2(1):77–83.
   PubMed Web of Science ®Google Scholar
• Omidfar K, Shirvani Z. Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting. DNA Cell Biol. 2012;31(6):1015–1026.
   PubMed Web of Science ®Google Scholar
• Farajnia S, Ahmadzadeh V, Tanomand A, et al. Development trends for generation of single-chain antibody fragments. Immunopharmacol Immunotoxicol. 2014;36(5):297–308.
   PubMed Web of Science ®Google Scholar
• Trejtnar F, Laznicek M. Analysis of renal handling of radiopharmaceuticals. Q J Nucl Med. 2002;46(3):181–194.
   PubMedGoogle Scholar
• Müller KM, Arndt KM, Plückthun A. A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett. 1998;432(1–2):45–49.
   PubMed Web of Science ®Google Scholar
• Müller KM, Arndt KM, Strittmatter W, et al. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett. 1998;422(2):259–264.
   PubMed Web of Science ®Google Scholar
• Lutterbuese R, Raum T, Kischel R, et al.. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S. 2010;107(28):12605–12610.
   PubMed Web of Science ®Google Scholar
• Bostrom J, Yu S-F, Kan D, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science. 2009;323(5921):1610–1614.
   PubMed Web of Science ®Google Scholar
• Schaefer G, Haber L, Crocker LM, et al.. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell. 2011;20(4):472–486.
   PubMed Web of Science ®Google Scholar
• Brezski RJ, Georgiou G. Immunoglobulin isotype knowledge and application to Fc engineering. Curr Opin Immunol. 2016 May;40:62–69.
   PubMed Web of Science ®Google Scholar
• Liu G, Tu D, Lewis M, et al. Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clin Cancer Res. 2016;22(10):2435–2444.
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K, Parveen A, et al. Antibody-drug conjugates as drug carrier systems for bioactive agents. Int J Polym Mater Polym Biomater. 2016;65(1):1–10.
   Web of Science ®Google Scholar
• Chari RVJ, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed. 2014;53(15):3796–3827.
   PubMed Web of Science ®Google Scholar
• Kim EG, Kim KM. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomol Ther. 2015;23(6):493–509.
   PubMed Web of Science ®Google Scholar
• Koefoed K, Steinaa L, Søderberg JN, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs. 2011;3(6):584–595.
   PubMed Web of Science ®Google Scholar
• Kearns JD, Bukhalid R, Sevecka M, et al. Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic. Mol Cancer Ther. 2015;14(7):1625–1636.
   PubMed Web of Science ®Google Scholar
• Arena S, Siravegna G, Mussolin B, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016;8(324ra14):1–10.
   Google Scholar
• Main ERG, Lowe AR, Mochrie SGJ, et al. A recurring theme in protein engineering: the design, stability and folding of repeat proteins. Curr Opin Struct Biol. 2005;15(4):464–471.
   PubMed Web of Science ®Google Scholar
• Plückthun A. Designed Ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489–511.
   PubMed Web of Science ®Google Scholar
• Forrer P, Stumpp MT, Binz HK, et al. A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett. 2003;539(13):2–6.
   PubMed Web of Science ®Google Scholar
• Interlandi G, Wetzel SK, Settanni G, et al. Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments. J Mol Biol. 2008;375(3):837–854.
   PubMed Web of Science ®Google Scholar
• Steiner D, Forrer P, Plückthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol. 2008;382(5):1211–1227.
   PubMed Web of Science ®Google Scholar
• Boersma YL, Chao G, Steiner D, et al. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem. 2011;286(48):41273–41285.
   PubMed Web of Science ®Google Scholar
• Boersma YL, Plückthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol. 2011;22(6):849–857.
   PubMed Web of Science ®Google Scholar
• Enkhbayar P, Kamiya M, Osaki M, et al. Structural principles of leucine-rich repeat (LRR) proteins. Proteins Struct Funct Bioinform. 2004;54(3):394–403.
   PubMed Web of Science ®Google Scholar
• Lee S-CS-G, Park K, Han J, et al. Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering. Proc Natl Acad Sci. 2012;109(9):3299–3304.
   PubMed Web of Science ®Google Scholar
• Lee -J-J, Choi H-J, Yun M, et al.. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed. 2015;54(41):12020–12024.
   PubMed Web of Science ®Google Scholar
• Sihver W, Pietzsch J, Krause M, et al. Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy. Pharmaceuticals. 2014;7(3):311–338.
   Google Scholar
• Cuartero-Plaza A, Mart??nez-Miralles E, Rosell R, et al. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res. 1996;2(1):13–20.
   PubMed Web of Science ®Google Scholar
• Friedman M, Nordberg E, Hoiden-Guthenberg I, et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel. 2007;20(4):189–199.
   PubMed Web of Science ®Google Scholar
• Löfblom J, Frejd FY, Ståhl S. Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol. 2011;22(6):843–848.
   PubMed Web of Science ®Google Scholar
• Justino CIL, Duarte AC, Rocha-Santos TAP. Analytical applications of affibodies. TrAC Trends Anal Chem. 2015;65:73–82.
   Web of Science ®Google Scholar
• Tolmachev V, Rosik D, Wållberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 2010;37(3):613–622.
   PubMed Web of Science ®Google Scholar
• Dickinson CD, Veerapandian B, Dai X-P, et al. Crystal structure of the tenth type III cell adhesion module of human fibronectin. J Mol Biol. 1994;236(4):1079–1092.
   PubMed Web of Science ®Google Scholar
• Main AL, Harvey TS, Baron M, et al. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell. 1992;71(4):671–678.
   PubMed Web of Science ®Google Scholar
• Koide A, Bailey CW, Huang X, et al. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol. 1998;284(4):1141–1151.
   PubMed Web of Science ®Google Scholar
• Hackel BJ, Ackerman ME, Howland SW, et al. Stability and CDR composition biases Enrich binder functionality landscapes. J Mol Biol. 2010;401(1):84–96.
   PubMed Web of Science ®Google Scholar
• Emanuel SL, Engle LJ, Chao G, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs. 2011;3(1):38–48.
   PubMed Web of Science ®Google Scholar
• Ramamurthy V, Krystek SR, Bush A, et al.. Structures of adnectin/protein complexes reveal an expanded binding footprint. Structure. 2012;20(2):259–269.
   PubMed Web of Science ®Google Scholar
• Hackel BJ, Kimura RH, Gambhir SS. Use of 64Cu-labeled fibronectin domain with EGFR- overexpressing tumor xenograft: molecular imaging. Radiology. 2012;263(1):179–188.
   PubMed Web of Science ®Google Scholar
• Yan Y, Chen G, Wei H, et al.. Fast Photochemical Oxidation of Proteins (FPOP) maps the epitope of EGFR binding to Adnectin. J Am Soc Mass Spectrom. 2014;25(12):2084–2092.
   PubMed Web of Science ®Google Scholar
• Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005;5(1):111–124.
   PubMed Web of Science ®Google Scholar
• Arbabi Ghahroudi M, Desmyter A, Wyns L, et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414(3):521–526.
   PubMed Web of Science ®Google Scholar
• Kijanka M, Dorresteijn B, Oliveira S, et al. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond). 2015;10(1):161–174.
   PubMed Web of Science ®Google Scholar
• Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother. 2007;56(3):303–317.
   PubMed Web of Science ®Google Scholar
• Schmitz KR, Bagchi A, Roovers RC, et al.. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure. 2013;21(7):1214–1224.
   PubMed Web of Science ®Google Scholar
• Roovers RC, Vosjan MJWD, Laeremans T, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011;129(8):2013–2024.
   PubMed Web of Science ®Google Scholar
• Heukers R, Vermeulen JF, Fereidouni F, et al. Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif. J Cell Sci. 2013;126(21):4900–4912.
   PubMed Web of Science ®Google Scholar
• Van Der Meel R, Oliveira S, Altintas I, et al. Tumor-targeted Nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release. 2012;159(2):281–289.
   PubMed Web of Science ®Google Scholar
• Oliveira S, Schiffelers RM, Van Der Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010;145(2):165–175.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. Faseb J. 2005;19(14):1978–1985.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Takasugi H, Aizawa T, et al. Peptide mimics of epidermal growth factor (EGF) with antagonistic activity. J Biotechnol. 2005;116(3):211–219.
   PubMed Web of Science ®Google Scholar
• Song S, Liu D, Peng J, et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. Faseb J. 2009;23:1396–1404.
   PubMed Web of Science ®Google Scholar
• Mizuguchi T, Ohara N, Iida M, et al.. Evaluation of dimerization-inhibitory activities of cyclic peptides containing a β-hairpin loop sequence of the EGF receptor. Bioorg Med Chem. 2012;20(19):5730–5737.
   PubMed Web of Science ®Google Scholar
• Hanold LE, Oruganty K, Ton NT, et al. Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics. PLoS One. 2015;10(3):e0118796.
   Web of Science ®Google Scholar
• Ahsan A, Ray D, Ramanand SG, et al. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J Biol Chem. 2013;288(37):26879–26886.
   PubMed Web of Science ®Google Scholar
• Collet G, Grillon C, Nadim M, et al. Trojan horse at cellular level for tumor gene therapies. Gene. 2013;525(2):208–216.
   PubMed Web of Science ®Google Scholar
• Jain PK, El-Sayed IH, El-Sayed MA. Au nanoparticles target cancer. Nano Today. 2007;2(1):18–29.
   Web of Science ®Google Scholar
• Altintas I, Heukers R, Van Der Meel R, et al. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J Control Release. 2013;165(2):110–118.
   PubMed Web of Science ®Google Scholar
• Li W, Liu Z, Li C, et al. Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression. J Cancer Res Clin Oncol. 2016;142(3):619–632.
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Greiser U, et al.. Epidermal Growth Factor Receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. Control. 2003;63(12):3154–3161.
   Google Scholar
• Hagen S, Baumann T, Wagner HJ, et al. Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Sci Rep. 2014;4:3759.
   PubMed Web of Science ®Google Scholar
• Conner J, Braidwood L, Brown SM. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Gene Ther. 2008;15(24):1579–1592.
   PubMed Web of Science ®Google Scholar
• Piao Y, Jiang H, Alemany R, et al. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther. 2009;16(3):256–265.
   PubMed Web of Science ®Google Scholar
• Verheije MH, Lamfers MLM, Würdinger T, et al. Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma. J Virol. 2009;83(15):7507–7516.
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1(11):1311–1318.
   PubMed Web of Science ®Google Scholar
• Mateo C, Moreno E, Amour K, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997;3(1):71–81.
   PubMedGoogle Scholar
• Bleeker WK, Van Bueren JJ, Van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173(7):4699–4707.
   PubMed Web of Science ®Google Scholar
• Murthy U, Basu A, Rodeck U, et al. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys. 1987;252(2):549–560.
   PubMed Web of Science ®Google Scholar
• Wersäll P, Ohlsson I, Biberfeld P, et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother. 1997;44(3):157–164.
   PubMed Web of Science ®Google Scholar
• Kettleborough CA, Saldanha J, Heath VJ, et al. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 1991;4(7):773–783.
   PubMedGoogle Scholar
• Dean C, Modjtahedi H, Eccles S, et al. Immunotherapy with antibodies to the EGF receptor. Int J Cancer Suppl. 1994;8:103–107.
   PubMedGoogle Scholar
• Gerdes CA, Nicolini VG, Herter S, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti - EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013;19(5):1126–1138.
   PubMed Web of Science ®Google Scholar
• Panousis C, Rayzman VM, Johns TG, et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer. 2005;92(6):1069–1077.
   PubMed Web of Science ®Google Scholar
• Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;128(2):438–445.
   Google Scholar
• Zalutsky MR, Boskovitz A, Kuan CT, et al. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol. 2012;39(1):23–34.
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Bao X, Keir ST, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res. 2013;19(17):4717–4727.
   PubMed Web of Science ®Google Scholar
• Winkler ME, O’Connor L, Winget M, et al. Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor. Biochemistry. 1989;28(15):6373–6378.
   PubMed Web of Science ®Google Scholar
• Chao G, Cochran JR, Dane Wittrup K. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol. 2004;342(2):539–550.
   PubMed Web of Science ®Google Scholar
• Gool HC, Hounsell EF, Lax I, et al. The carbohydrate specificities of the monoclonal antibodies 29.1, 445 and 3C1B12 to the epidermal growth factor receptor of A431 cells. Biosci Rep. 1985;5(1):83–94.
   PubMed Web of Science ®Google Scholar
• Lorimer IA, Keppler-Hafkemeyer A, Beers RA, et al. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A. 1996;93(25):14815–14820.
   PubMed Web of Science ®Google Scholar
• Huang L, Gainkam LOT, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008;10(3):167–175.
   PubMed Web of Science ®Google Scholar
• Nevoltris D, Lombard B, Dupuis E, et al. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers. ACS Nano. 2015;9(2):1388–1399.
   PubMed Web of Science ®Google Scholar
• Friedman M, Orlova A, Johansson E, et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol. 2008;376(5):1388–1402.
   PubMed Web of Science ®Google Scholar
• Hackel BJ, Sathirachinda A, Gambhir SS. Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution. Protein Eng Des Selection. 2012;25(10):639–647.
   PubMed Web of Science ®Google Scholar
• Fury MG, Lipton A, Smith KM, et al. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother. 2008;57(2):155–163.
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Ludwig D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem. 2004;279(4):2856–2865.
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005;280(20):19665–19672.
   PubMed Web of Science ®Google Scholar
• Choi BD, Kuan C-T, Cai M, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A. 2013;110(1):270–275.
   PubMed Web of Science ®Google Scholar
• Castoldi R, Ecker V, Wiehle L, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene. 2013;32(50):5593–5601.
   PubMed Web of Science ®Google Scholar
• Lee JM, Lee SH, Hwang J-W, et al.. Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. Oncogene. 2016;1–10. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Hu S, Fu W, Xu W, et al.. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res. 2015;75(1):159–170.
   PubMed Web of Science ®Google Scholar
• Reusch U, Sundaram M, Davol PA, et al. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006;12(1):183–190.
   PubMed Web of Science ®Google Scholar
• Zitron IM, Thakur A, Norkina O, et al. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer. 2013;13(83):1–14.
   PubMed Web of Science ®Google Scholar
• Von MB, Thakur M, Weng A, et al. Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma. Futur Oncol. 2014;10(14):2161–2175.
   PubMed Web of Science ®Google Scholar
• Li J, Chen L, Liu N, et al. EGF-coated nano-dendriplexes for tumor-targeted nucleic acid delivery in vivo. Drug Deliv. 2016;23(5):1718–1725.
   Google Scholar
• Li X, Qiu L, Zhu P, et al. Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting. Small. 2012;8(16):2505–2514.
   PubMed Web of Science ®Google Scholar
• Hanold LE, Watkins CP, Ton NT, et al. Design of a selenylsulfide-bridged EGFR dimerization arm mimic. Bioorg Med Chem. 2015;23(12):2761–2766.
   PubMed Web of Science ®Google Scholar
• Xu R, Povlsen GK, Soroka V, et al. A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo. Cell Oncol. 2010;32(4):259–274.
   PubMed Web of Science ®Google Scholar
• Mizuguchi T, Uchimura H, Kakizawa T, et al. Inhibitory effect of a dimerization-arm-mimetic peptide on EGF receptor activation. Bioorganic Med Chem Lett. 2009;19(12):3279–3282.
   PubMed Web of Science ®Google Scholar
• Liu W-J, Liu X-J, Li L, et al. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation. Cancer Immunol Immunother. 2014;63(12):1261–1272.
   PubMed Web of Science ®Google Scholar
• Campa MJ, Kuan C-T, O’Connor-McCourt MD, et al. Design of a novel small peptide targeted against a tumor-specific receptor. Biochem Biophys Res Commun. 2000;275(2):631–636.
   PubMed Web of Science ®Google Scholar
• Cardó-Vila M, Giordano RJ, Sidman RL, et al. From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A. 2010;107(11):5118–5123.
   PubMed Web of Science ®Google Scholar
• Guardiola S, Díaz-Lobo M, Seco J, et al.. Peptides targeting EGF block the EGF-EGFR interaction. Chembiochem. 2015. doi:10.1002/cb.
   Web of Science ®Google Scholar
• Yu Y, Rishi AK, Turner JR, et al. Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol. 2001;280(5):C1083–C1089.
   PubMed Web of Science ®Google Scholar
• Hagen S, Baumann T, Wagner HJ, et al. Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Sci Rep. 2014;4(3759):1–11.
   Google Scholar
• Nakamura T, Peng K-W, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005;23(2):209–214.
   PubMed Web of Science ®Google Scholar
• Watkins SJ, Mesyanzhinov VV, Kurochkina LP, et al. The “adenobody” approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 1997;4(10):1004–1012.
   PubMed Web of Science ®Google Scholar
• Hemminki A, Dmitriev I, Liu B, et al. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. 2001;61(17):6377–6381.
   PubMed Web of Science ®Google Scholar
• Dreier B, Honegger A, Hess C, et al.. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A. 2013;110(10):E869–E877.
   PubMed Web of Science ®Google Scholar
• Dai H-S, Liu Z, Jiang W, et al. Directed evolution of a virus exclusively utilizing human epidermal growth factor receptor as the entry receptor. J Virol. 2013;87(20):11231–11243.
   PubMed Web of Science ®Google Scholar
• Uusi-Kerttula H, Legut M, Davies J, et al. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies. Hum Gene Ther. 2015;26(5):320–329.
   PubMed Web of Science ®Google Scholar
• Grandi P, Fernandez J, Szentirmai O, et al. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Ther. 2010;17(9):655–663.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Pinard M, Jaime J, et al. A ligand-pseudoreceptor system based onde novo designed peptides for the generation of adenoviral vectors with altered tropism. J Gene Med. 2008;10(4):355–367.
   PubMed Web of Science ®Google Scholar
• Grünwald GK, Vetter A, Klutz K, et al. EGFR-targeted adenovirus dendrimer coating for improved systemic delivery of the theranostic NIS gene. Mol Ther Nucleic Acids. 2013;2:e131.
   PubMedGoogle Scholar
• Huhtala T, Kaikkonen MU, Lesch HP, et al. Biodistribution and antitumor effect of Cetuximab-targeted lentivirus. Nucl Med Biol. 2014;41(1):77–83.
   PubMed Web of Science ®Google Scholar
• Kaikkonen MU, Lesch HP, Pikkarainen J, et al. (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery. Gene Ther. 2009;16(7):894–904.
   PubMed Web of Science ®Google Scholar